|
Originally published In Press as doi:10.1074/jbc.M108845200 on January 25, 2002
J. Biol. Chem., Vol. 277, Issue 15, 12613-12621, April 12, 2002
Yeast Expression and NMR Analysis of the Extracellular Domain of
Muscle Nicotinic Acetylcholine Receptor Subunit*
Yun
Yao ,
Junmei
Wang ,
Nitnara
Viroonchatapan ,
Avraham
Samson§,
Jordan
Chill§,
Elizabeth
Rothe ,
Jacob
Anglister§¶, and
Zuo-Zhong
Wang
From the Department of Neurobiology,
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
15261 and the § Department of Structural Biology, the
Weizmann Institute of Science, Rehovot 76100, Israel
Received for publication, September 13, 2001, and in revised form, January 24, 2002
 |
ABSTRACT |
The subunit of the nicotinic
acetylcholine receptor (AChR) from Torpedo electric organ
and mammalian muscle contains high affinity binding sites for
-bungarotoxin and for autoimmune antibodies in sera of patients with
myasthenia gravis. To obtain sufficient materials for structural
studies of the receptor-ligand complexes, we have expressed part of the
mouse muscle subunit as a soluble, secretory protein using the
yeast Pichia pastoris. By testing a series of truncated
fragments of the receptor protein, we show that 211, the entire
amino-terminal extracellular domain of AChR subunit (amino acids
1-211), is the minimal segment that could fold properly in yeast. The
211 protein was secreted into the culture medium at a concentration
of >3 mg/liter. It migrated as a 31-kDa polypeptide with
N-linked glycosylation on SDS-polyacrylamide gel. The
protein was purified to homogeneity by isoelectric focusing electrophoresis (pI 5.8), and it appeared as a 4.5 S monomer on sucrose
gradient at concentrations up to 1 mM (~30 mg/ml). The receptor domain bound monoclonal antibody mAb35, a
conformation-specific antibody against the main immunogenic region of
the AChR. In addition, it formed a high affinity complex with
-bungarotoxin (kD 0.2 nM) but
showed relatively low affinity to the small cholinergic ligand
acetylcholine. Circular dichroism spectroscopy of 211 revealed a
composition of secondary structure corresponding to a folded protein.
Furthermore, the receptor fragment was efficiently 15N-labeled in P. pastoris, and proton
cross-peaks were well dispersed in nuclear Overhauser effect and
heteronuclear single quantum coherence spectra as measured by NMR
spectroscopy. We conclude that the soluble AChR protein is useful for
high resolution structural studies.
 |
INTRODUCTION |
The nicotinic AChRs1 are
members of the superfamily of ligand-gated ion channels that mediate
fast ion flow across postsynaptic membranes in neural and muscle cells.
This family of proteins includes the receptors for glycine,
-aminobutyric acid, glutamate, and serotonin (1, 2). The AChR from
Torpedo electric organ and skeletal muscle is a large
(~290 kDa) heteropentameric complex consisting of four homologous
subunits in the stoichiometry of 2 
(Torpedo and embryonic muscle) or 2 
(adult muscle (3, 4)). The subunits are arranged in the order
- - - - to create a cylindrical complex around the ion
channel (5-7). Each subunit is a single polypeptide chain that has a
large extracellular amino-terminal domain followed by three
transmembrane domains, a long intracellular loop, a fourth
transmembrane domain, and a short extracellular carboxyl-terminal tail
(8-10). The large extracellular domain of the AChR confers high
affinity binding activity for major agonists and competitive
antagonists. The neurotransmitter ACh interacts with two nonequivalent
sites near the interface of the  and  subunits (2, 11, 12).
The binding site for -bungarotoxin ( -BuTx) is located largely on
the amino-terminal extracellular domain of the subunit (13-16). In
addition, this part of the subunit also possesses the main immunogenic
region, which stimulates the production and forms the binding
site for autoimmune antibodies in sera of patients with myasthenia
gravis (17).
In early binding studies using synthetic peptides corresponding to
sequences of Torpedo subunit, a major determinant of the
-BuTx binding site, was mapped to residues 185-196 and the main
immunogenic region to residues 67-76, respectively (15, 18-22).
Recent NMR studies have delineated further the structural details of
the toxin-peptide complexes (23, 24). In comparison with the
full-length subunit, however, the peptide ligands bound -BuTx
with significantly lower affinities, suggesting that other residues
outside of the peptide sequence may be part of the high affinity
binding sites found on the native receptor protein (15, 25, 26).
Electron microscopic studies have imaged the intact Torpedo
AChR proteins at a resolution of 4.6 Å but were unable to reveal great
details of the ligand binding sites (27). Recently, an ACh-binding
protein (AChBP) from glial cells of the snail Lymnaea stagnalis has been crystallized (28). The molluscan AChBP is a
soluble protein with 210 amino acids, which shares structural similarities with extracellular domains of the nicotinic AChR. Notably,
23.9% of residues in the protein were found to be identical to the
7 subtype neuronal AChR (29). However, the AChR-binding protein has
much lower sequence identity with the subunits of Torpedo and muscle AChR. In addition, the snail protein does
not possess the main immunogenic region epitope for interaction with autoimmune antibodies, and structural attributes of the -BuTx binding site on the AChR-binding protein remain unknown.
Structural analysis of AChR at atomic resolution has been hampered by
an insufficient supply of native receptor proteins and the difficulty
in crystallizing membrane proteins. The full-length and truncated
fragments of AChR subunits have been expressed as folded proteins in
Xenopus oocytes, and mammalian and baculovirus-infected insect cells (30-34). These eukaryotic expression systems, however, were incapable of producing milligram quantities of receptor material needed for structural determination. Bacterial expression of AChR proteins has proven to be problematic because of the denaturing conditions required to solubilize the protein and aggregation of
receptor subunits (35-38). In previous studies, we have shown that the
entire amino-terminal extracellular domain of mouse muscle AChR subunit ( 211) can fold properly in the absence of other parts of the
receptor subunit, and the protein is secreted to the culture medium
when expressed in transfected COS cells (39, 40). Here we have made use
of the yeast Pichia pastoris to generate large quantities of
211 as a soluble protein. The yeast-produced receptor domain
includes the appropriate post-translational modifications and forms
high affinity complexes with -BuTx and the monoclonal antibody
mAb35. Circular dichroism (CD) and NMR measurement further suggest that
the protein was properly folded and hence amenable to structural
determination by x-ray diffraction and multidimensional NMR techniques.
 |
EXPERIMENTAL PROCEDURES |
cDNAs, Expression Vectors, Strains, and Antisera--
The
full-length cDNA coding for the mouse muscle AChR subunit was
kindly provided by the late Dr. John Merlie (Washington University, St.
Louis (41)). The yeast expression vector pPICZ A and
P. pastoris strain KM71 mutS were purchased from
Invitrogen. mAb210 and mAb35, two monoclonal antibodies against the
NH2-terminal extracellular domain of the AChR subunit,
were purchased from CRP Inc. (Richmond, CA (42,43)).
Chemicals and Reagents--
Restriction and modification enzymes
for DNA cloning were purchased from Invitrogen. Endoglycosidase H (Endo
H) was obtained from New England Biolabs, Inc. (Beverly, MA). Synthetic
oligonucleotide primers were made by Integrated DNA Technology
(Coralville, IA). Nickel-nitrilotriacetic acid (Ni-NTA) metal affinity
resin was the product of Qiagen, Inc. (Valencia, CA).
[15N]Ammonium sulfate was obtained from Cambridge Isotope
Laboratories (Andover, MA). -125I-BuTx was
purchased from Amersham Biosciences. Unlabeled -BuTx and all other
chemicals were obtained from Sigma.
Constructs of AChR Subunit--
All amino acids were
numbered according to their position in the mature protein sequence.
The cDNA construct 211 encodes the entire
NH2-terminal extracellular portion of mouse muscle AChR subunit (from amino acid serine at position 1 up to proline at position
211; see Fig. 1A). It was made
by amplification of the corresponding sequence in the full-length subunit cDNA using PCRs. cDNA constructs 216 and M1
express proteins containing the entire extracellular domain plus the
first 6 amino acids of the first transmembrane domain (M1) and the
complete M1 domain (up to amino acid 241) of the subunit,
respectively.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 1.
Expression of amino-terminal extracellular
domains of mouse muscle AChR subunit in
P. pastoris. Panel A, schematic
representation of subunit fragments expressed in yeast.
Top, protein encoded by full-length subunit cDNA.
Bottom, proteins encoded by a set of truncated subunit
cDNAs containing deletions in the carboxyl- or amino-terminal
portion of the coding region. The numbers indicate the first
and the last amino acids encoded by each of the truncated subunit
cDNAs. Sequences are shown in one-letter amino acid notation.
Hydrophobic transmembrane domains of the constructs are shown in
black. Panel B, expression levels of subunit
fragments vary with the length of the constructs. 48 h after
methanol induction, the culture supernatant was collected by
centrifugation. Total subunit proteins secreted were separated by
SDS-PAGE and immunoblotted with mAb210. Panel C, the amount
of folded receptor proteins in culture supernatant was determined by
-BuTx binding assays. 10 µl of yeast culture medium was incubated
with 5 nM -125I-BuTx in a buffer containing
0.1 M sodium phosphate (pH 7.4), 0.25 M NaCl,
and 0.5% bovine serum albumin for 1.5 h at 4 °C. Toxin binding
activities were determined by immunoprecipitation using the subunit-specific monoclonal antibody, mAb210. Each data point
represents results obtained from four separate experiments.
|
|
cDNAs encoding shorter fragments of the extracellular domain of the
subunit were created in a similar way by PCR amplification. The
carboxyl-terminal deletion constructs 207, 208, 209, and 210 encode the extracellular domain starting at amino acid number 1 (serine) and terminating immediately after amino acid number
207, 208, 209, and 210, respectively. The amino-terminal deletion
constructs 5-211, 10-211, and 15-211 code for subunit proteins whose sequences start at amino acid 5, 10, and 15 of the
mature mouse AChR, respectively, and they all terminate immediately after amino acid 211 (Fig. 1A). For the convenience of
cloning, an EcoRI site (GAATTC) was added to the 5'-end of
all forward PCR primers, thereby introducing two additional amino acids
(Glu and Phe) to the amino terminus of each subunit protein. These two residues did not affect protein folding and the level of expression (data not shown). Besides, an XbaI site (TCTAGA) was added
to the 3'-end of all reverse primers after the stop codon. After amplification by PCR, the cDNA products were digested with
EcoRI/XbaI. They were then cloned into
EcoRI/XbaI sites of the Pichia
expression vector pPICZ A, downstream of the sequence for
the -mating factor signal peptide from Saccharomyces
cerevisiae and the Glu-Ala-Glu-Ala repeat sequence (44). The
sequence of all constructs was confirmed by automated DNA sequencing
(performed at the University of Pittsburgh Biotech Center).
Yeast Transformation and Screening of Positive
Clones--
Plasmids carrying receptor cDNA constructs were
linearized with the restriction enzyme PmeI and transformed
by electroporation into the KM71 mutS strain of
P. pastoris (45). The promoter regulating the production of
alcohol oxidase (aox1) was used to drive the expression of
the receptor protein (46, 47). Positive transformants with receptor
cDNA integrated into the aox1 locus on yeast chromosome
were selected by growth on plates with Zeocin (Invitrogen). Single
colonies were picked up randomly from the plates, and each was grown in
2 ml of the induction medium BMMY (1% yeast extract, 2% peptone, 0.1 M potassium phosphate (pH 6.0), and 1% methanol) at
30 °C. After 48 h in culture, the supernatant was collected by
centrifugation, and subunit proteins secreted were determined by
immunoblotting with mAb210 and by measuring -125I-BuTx
binding activity (39). Clones that secreted the highest level of the
receptor protein were chosen for large scale protein expression experiments.
Large Scale Expression and Purification of 211
Protein--
The cDNA construct employed for large scale
expression of 211 protein was tagged by an 18-nucleotide sequence
encoding hexahistidine residues at the 3'-end of 211 coding region
before the stop codon. In addition, a sequence for the FLAG tag
(DYKDDDDK) was fused in-frame to the 5'-end of 211 cDNA
(Fig. 2A). The dual epitope tags facilitated protein purification and enhanced secretion of 211
in yeast (Fig. 2A). The expression cassette was subcloned into the vector pPICZaA and stably transformed into a
KM71 mutS yeast strain
(His3+). A single colony harboring the 211
cDNA was grown in 50 ml of BMGY medium (1% yeast extract, 2%
peptone, 0.1 M potassium phosphate (pH 6.0), and 1%
glycerol) at 30 °C in an incubator shaker overnight. The starting
culture was used to inoculate 1 liter of a minimal medium containing
0.1 M potassium phosphate (pH 7.0), 3.4 g of yeast
nitrogen base without amino acid, 0.5 g of ammonium sulfate,
0.0004 g of biotin, and 0.5 g of sorbitol. For 15N
labeling of the receptor protein, unlabeled ammonium sulfate was
replaced by [15N]ammonium sulfate. The culture was grown
in batch mode in a 1.25-liter vessel on a New Brunswick BioFlo 3000 Fermentor at 30 °C. Agitation speed was set at 350 rpm, and the
dissolved oxygen concentration was maintained above 25% through the
entire fermentation process. 0.5% methanol and 0.05% sorbitol were
added each day to induce protein expression and to increase the cell
density. At 48 h after growth in the minimal medium, yeast
supernatant was harvested by centrifugation, loaded on to a metal
affinity column packed with Ni-NTA Superflow resin, washed with 250 mM NaCl plus 10 mM imidazole in 50 mM phosphate-buffered saline (pH 7.4), and eluted with 200 mM imidazole in 50 mM phosphate buffer (pH
7.4). The protein was dialyzed in 5 mM phosphate buffer (pH
7.4), and concentrated using Aquacide II (Calbiochem-Novabiochem Corp.,
San Diego). The sample was then purified using the Rotofor IEF system
(Bio-Rad). A small aliquot was taken from each of the fractions,
separated by SDS-PAGE, and detected with SimplyBlue SafeStain
(Invitrogen). Fractions containing pure 211 protein were pooled,
concentrated, and loaded onto a HiPrep26/10 desalting column (Amersham
Biosciences) to remove the ampholytes.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 2.
Optimization of conditions for
211 expression in Pichia.
Panel A, diagram of the expression cassette, which includes
the signal sequence from the -mating factor of S. cerevisiae, a Glu-Ala-Glu-Ala repeat, the FLAG/hexahistidine tags,
and the 211 protein. The arrow indicates the site where
signal peptide cleavage is predicted to occur in Pichia. 20 µl of yeast culture medium was incubated with 5 nM
-125I-BuTx in a buffer containing 0.1 M
sodium phosphate (pH 7.4), 0.25 M NaCl, and 0.5% bovine
serum albumin for 1.5 h at 4 °C. Bound
-125I-BuTx was pulled down by immunoprecipitation using
mAb210 and protein G-Sepharose beads and counted with a gamma counter.
The concentration of 211 protein was calculated based on the level
of precipitated radioactivity and the specific activity of 220 Ci/mmol
-125I-BuTx. Panel B, the copy number of the
expression cassette affects secretion of 211 protein in
Pichia. 211 protein was purified from the yeast culture
medium using a Ni-NTA column. Protein concentration was determined by
the BCA method. Panel C, Pichia was grown in
culture media with different compositions. 48 h after methanol
induction, the 211 protein was purified from the culture supernatant
using a Ni-NTA column. Protein concentration was determined by the BCA
method. Each data point represents results obtained from four separate
experiments.
|
|
Protein Analysis--
The recombinant proteins were
characterized with several biochemical and biophysical techniques.
SDS-PAGE using 12.5% gels was carried out based on the method of
Laemmli (48). Western immunoblotting experiments were performed as
described by Wang et al. (39). Protein concentrations were
routinely measured using a BCA colorimetric assay (Pierce) with bovine
serum albumin as standard. Protein deglycosylation was carried out by
incubating a purified protein sample with Endo H in 50 mM
sodium phosphate buffer (pH 7.4), at 37 °C for 2 h. Sucrose
gradient ultracentrifugation was performed as described by Wang
et al. (39). Circular dichroism spectra were measured in a
CD spectrometer (Aviv model 202) with the purified protein in 20 mM Tris (pH 7.4) at 22 °C.
Ligand Binding Studies--
Radioligand binding at equilibrium
was determined using a pull-down assay with the Ni-NTA Superflow resin.
Briefly, protein samples were incubated with 220 Ci/mmol
-125I-BuTx (Amersham Biosciences) in a buffer containing
0.1 M sodium phosphate, 0.25 M NaCl, and 0.5%
bovine serum albumin at 4 °C. 40 µl of Ni-NTA Superflow resin was
added to each reaction tube and incubated for an additional 30 min in a
rotary mixer. The resins were precipitated by centrifugation, washed
with phosphate-buffered saline, and counted for bound
-125I-BuTx with a gamma counter.
The kinetics of association was measured by incubating 211 protein
with -125I-BuTx at room temperature. To quantify the
amount of toxin-receptor complex formed at various times after
initiation of the reaction, the mixture was filtered through a Ni-NTA
minicolumn (Qiagen), washed briefly, and counted for bound radioligand
with a gamma counter. The association constant,
kon, was calculated from the time course of
association using the integrated second order rate equation (49).
|
(Eq. 1)
|
In Equation 1 (L)T is the total
concentration of -125I-BuTx, (R)T
the total concentration of 211 protein, (LR)e
the concentration of the toxin- 211 complex at equilibrium, and
(LR) the concentration of toxin- 211 complex at time
t.
To study the kinetics of dissociation
(koff), toxin binding was allowed to reach
equilibrium (90 min). Excess cold 20 µM toxin was then
added to initiate dissociation, and the amount of bound -125I-BuTx was determined at the indicated times. The
first order rate constant of dissociation was determined using Equation 2 (49). In this equation, (LR)0 is the
concentration of the toxin- 211 complex just prior to addition of
excess cold toxin, and (LR) is the concentration of complex
at time t after the initial dissociation. Division of
koff by kon gave the
KD value.
|
(Eq. 2)
|
In competition studies with small cholinergic ligands, the
concentrations of 211 and -125I-BuTx were kept
constant at 1 and 5 nM, respectively. Toxin binding activity in the absence of small ligands was normalized to 100%, and
the amount of bound ligands was calculated from the reduction in
-125I-BuTx binding. KI values
were calculated from the IC50 concentration of competing
ligands by the equation of Cheng and Prusoff (50).
NMR Measurement of 211 Protein--
Samples of unlabeled and
15N-labeled 211 protein were prepared and concentrated
to 10 mg/ml (0.32 mM) in 50 mM sodium phosphate (pH 7.4) and 50 mM sodium chloride. A two-dimensional
sensitivity-enhanced TROSY-15N-1H HSQC (51) and
a TROSY-three-dimensional 15N-separated NOESY spectra (52)
were measured at 25 °C on a Bruker DRX-800 MHz NMR spectrometer
equipped with a z-gradient triple resonance probe (Bruker). Acquisition
times and number of complex points in each dimension in the HSQC
spectrum were 25.8 ms, 700* (f2,
1HN) and 41.9 ms, 110* (f1,
15N). 12 scans were recorded for each hypercomplex point
for a total measurement time of 75 min. Acquisition times and number of
complex points in each dimension in the NOESY spectrum were 20.0 ms,
512* (f3, 1HN), 4.5 ms, 40*
(f2, 1H), and 11.4 ms, 24*
(f1, 15N), and the mixing time was
70 ms. 32 scans were recorded for each hypercomplex point for a total
measurement time of 57 h.
Selective flipback pulses on the water resonance were applied to
compensate for the faster exchange rate of the amide protons observed
at neutral and basic pH (53, 54). The WATERGATE (WATER suppression by
GrAdient Tailored Excitation) pulse sequence was applied for additional
water suppression (55). Data were processed and analyzed on an Octane
work station (Silicon Graphics) using XWINNMR and NMRPipe (56).
 |
RESULTS |
In previous studies we have shown that 211, the entire
amino-terminal extracellular domain of mouse AChR subunit, is
secreted as a soluble protein in transfected COS cells (39, 40). When the receptor domain with its native signal peptide sequence was expressed in P. pastoris, 211 protein was not detected in
yeast culture medium as measured by -125I-BuTx binding
activity. Immunoblotting of cell lysates using mAb210 indicated that
the native receptor signal sequence was not cleaved off, and the
protein was retained intracellularly. When the native signal peptide of
the receptor protein was replaced by a signal sequence from -mating
factor of S. cerevisiae, however, low levels of 211 were
secreted. A further increase in the secretion of 211 protein was
detected when a Glu-Ala-Glu-Ala repeat was placed between the yeast
signal peptide and 211 protein (data not shown and Ref. 44). Based
on these results, the signal peptide of yeast -mating factor and a
Glu-Ala-Glu-Ala repeat were employed for the expression of 211 in
all experiments described below.
Minimal Extracellular Domain of AChR Subunit--
In a
previous study using transiently transfected COS cells, we noted that
the levels of secretion of truncated extracellular fragments of AChR
subunit were affected markedly by the length of subunits expressed
(39). As the first step toward setting up the yeast expression system,
we sought to define a minimal domain of subunit which is able to
fold efficiently and give maximal secretion in P. pastoris.
In one set of the experiments, we tested a series of subunit
fragments whose carboxyl-terminal sequences were truncated. Thus, the
constructs 210, 209, 208, and 207 encode amino-terminal
extracellular domains terminated immediately after amino acid 210, 209, 208, and 207, respectively (Fig. 1A). Pichia
transformed with each of the mutant cDNAs was grown in BMMY and
induced to express the proteins with methanol. 48 h after
induction, the culture medium was collected by centrifugation, and
total subunit proteins secreted were detected by immunoblotting with mAb210 and protein G-Sepharose beads (39). As illustrated in Fig.
1B, 211 protein was produced at the highest level,
whereas other shorter fragments ( 210, 209 and 208, and 207)
were secreted at significantly lower levels. In contrast, fragments
with part ( 216) or the entire first transmembrane domain ( M1)
were hardly detectable in the culture supernatant. These longer
proteins are presumably retained in the endoplasmic reticulum as
integral membrane proteins. In fact, we have shown in a previous study
that they are resistant to extraction by alkaline buffers from
transfected COS cell membrane (39). To examine whether the
yeast-secreted proteins folded properly to assume a native
receptor-like conformation, we measured their binding activities to
-125I-BuTx. Among all of the fragments detected in yeast
medium, 211 folded most efficiently as shown by its high toxin
binding activity (Fig. 1C). Our data thus suggest that subunit sequences up to proline at position 211 are indispensable for
high level expression in Pichia.
In another set of experiments, we examined the expression of 211
protein with truncation of the NH2-terminal sequence. The cDNA constructs 5-211, 10-211, and 15-211 encode
proteins whose N terminus starts at amino acid 5, 10, and 15, respectively. The carboxyl termini of these constructs were terminated
immediately after residue 211. As shown in Fig. 1B,
truncation of the first five amino-terminal residues (construct
5-211) reduced the concentration of 211 protein in the culture
medium dramatically. When more residues at the amino terminus were
truncated as in the case of 10-211 and 15-211, little proteins
were secreted, and -125I-BuTx binding activity was
virtually undetectable in the yeast supernatant. Thus, we conclude that
amino acids 1-211 in the primary sequence of subunit constitute
the minimal ligand binding domain for efficient folding and secretion
in Pichia. Accordingly, the 211 construct was employed
for all experiments described below.
Factors That Affect the Secretion of 211 Protein--
Because a
major goal of our research is to obtain protein materials sufficient
for NMR measurement and for crystallization, we examined conditions
that are key to high level expression of the receptor domain in
Pichia. Epitope tagging by adding hexahistidine residues at
the carboxyl-terminal end of 211 protein had little effect on
protein yield but facilitated its purification by metal-chelating chromatography. Virtually all receptor domains in the culture supernatant bound the Ni-NTA resin, and ~95% of proteins eluted from
the column appeared to be 211 (Fig.
3A, lane 3). In
contrast, adding a FLAG tag (DYKDDDDK) to the amino terminus of 211
resulted in a remarkable increase in protein expression (Fig.
2A). Because the FLAG sequence is rich in charged residues,
it may possibly enhance the overall solubility of the extracellular
domain of the subunit and thus account for the increased secretion
of 211 in Pichia. For these reasons, we have employed the
211 construct with both FLAG and hexahistidine tags (see Fig.
2A) in all of the experiments described below (Figs.
2B through Fig. 9).

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 3.
Purification of 211
from the yeast culture medium. Panel A, SDS-PAGE
separation and Coomassie Blue staining of of crude and purified protein
samples. Lane 1, crude culture medium before induction;
lane 2, crude medium from 0.5% methanol-induced culture;
lane 3, 211 protein purified using a Ni-NTA column
followed by IEF (lane 4). The arrow indicates the
location of 211 protein on a 12.5% gel. Panel B,
purification of protein by IEF. Top, protein samples were
run in the Rotofor apparatus, fractionated, and separated by SDS-PAGE
(12.5% gel). The gel was stained with Coomassie Blue.
Bottom, 211 protein displays a pI value of ~5.8.
|
|
A major advantage of the Pichia expression system is more
than one copy of foreign genes can be integrated into the
aox1 loci on chromosome DNA by homologous recombination
(57). We have therefore introduced tandem expression cassettes
containing several copies of the FLAG/hexahistidine-tagged 211
cDNA to Pichia genome by electroporation. The effect of
cDNA copy number on the level of expression is depicted in Fig.
2B. Yeast with two copies of receptor cDNA secreted
highest level of 211 protein. Adding more copies of the cDNA
failed to enhance the expression of 211 further. In fact, protein
yields started to decrease in cells carrying more than four copies of
the expression cassette.
Pichia containing two copies of 211 cDNA was then
fermented in batch mode (see "Experimental Procedures"), and
optimal conditions for the culture were determined. In BMMY, a standard
rich medium used widely for protein expression in yeast, the cells
secreted ~1.4 mg/liter 211 protein. Surprisingly, the yield of
receptor protein increased to 2.1 mg/liter when the cells were grown in diluted BMMY medium (1/4 strength). Presumably the diluted
medium may help to prevent overproduction and aggregation of 211 in the ER of yeast cells and hence facilitate the secretion of folded proteins. To optimize conditions for 15N and
13C labeling of 211 protein, we have grown
Pichia in a protein-free minimal medium (pH 6.0). As shown
in Fig. 2C, little receptor protein was generated (0.2 mg/liter) because of the sluggish growth of the cells (OD ~2.0 at
48 h). Addition of sorbitol (0.5 g/liter) to the minimal medium
stimulated the growth of Pichia (OD ~14) and boosted
211 secretion (2.4 mg/liter). For many other recombinant proteins
that have been successfully expressed before, the optimal pH for
culture of Pichia was found to be 6.0 (57, 58). This condition, however, was not favorable for the expression of 211 presumably because it is close to the pI value (5.8) of the protein. In
fact, when the culture was carried out at pH 7.0, the amount of 211
secreted into the medium increased to >3 mg/liter (Fig. 2C).
Biochemical and Pharmacological Characterization of 211
Protein--
Because P. pastoris secreted very low levels
of yeast proteins, 211 thus comprised the vast majority of the
secretory proteins in the minimal medium, thereby simplifying the
purification procedures (Fig. 3A). It was readily purified
to >95% purity using metal-chelating chromatography with a Ni-NTA
column (Fig. 3A). IEF electrophoresis in the Rotofor
apparatus further purified the protein to homogeneity (Fig. 3,
A and B). At the end of purification, ~75% of
total receptor protein in the crude medium was recovered, and the final
yield of 211 was 2.3 mg/liter culture. Amino-terminal sequencing of an aliquot of the sample confirmed that complete signal peptide cleavage had occurred in the yeast (data not shown). The purified 211 showed a pI value of 5.8 on IEF (Fig. 3B) and
migrated as a 31 kDa single band on SDS-PAGE (Figs. 3A and
4A). Treatment with Endo H
reduced the size of the protein to ~28 kDa, indicating that it was
homogeneously glycosylated (Fig. 4A). When a
glycosylation-defective mutant (Asn141 Ala) of 211
was expressed in Pichia, we could not detect any receptor
proteins in the yeast culture medium, suggesting that the
N-linked glycosylation is essential for folding and
secretion of the receptor domain (data not shown).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 4.
Folding of the purified
211 protein. Panel A, 2 µg of
purified 211 protein was digested with Endo H, separated by
SDS-PAGE, and revealed by Coomassie Blue staining. Panel B,
the 211 protein interacts with -BuTx and mAb35. Lane
3, 2 µg of purified 211 protein on SDS-PAGE. Lane
4, the protein was precipitated with -BuTx-Sepharose 4B resin
and then separated by SDS-PAGE. Lane 6, 211 was
immunoprecipitated by mAb35 and protein G-Sepharose. In lane
5, excess free 0.5 µM -BuTx was included in the
pull-down assay by -BuTx-Sepharose 4B resin. Lane 7,
211 protein was not immunoprecipitated with nonimmune serum.
|
|
The yeast-secreted receptor protein folded correctly as determined in
the following two experiments. First, purified 211 bound to
-BuTx-conjugated Sepharose 4B resin in a pull-down assay (Fig.
4B). Inclusion of excess free 0.5 µM -BuTx
prevented protein binding to toxin beads, suggesting that the
interaction is specific. Second, the 211 protein could be
immunoprecipitated by mAb35, a mononclonal antibody against a
conformation-specific epitope in the amino-terminal extracellular
domain of AChR subunit (Fig. 4B and Refs. 42 and 43).
The antagonist binding affinity of 211 was determined quantitatively
in an equilibrium binding assay using -125I-BuTx as
radioligand (Fig. 5A). The
binding reaction was saturable with a KD value
of 1.2 ± 0.2 nM. A Scatchard plot of the data showed
that the purified receptor fragment contains a single class of
equivalent and independent binding site. Based on the
Bmax value of the binding reaction and the
binding capacity curve (Fig. 5, A and B), we
estimated that more than 95% of 211 protein employed in the assays
bound 125I-BuTx, suggesting a stoichiometry of 1:1 for the
toxin-receptor complex.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 5.
Saturation binding of
125I- -BuTx to purified
211 protein. Panel A, 1 nM purified 211 protein was incubated with various
concentrations of -125I-BuTx for 20 h. Bound toxin
was separated by precipitation with Ni-NTA beads, and the radioactivity
was measured in a gamma counter. Nonspecific binding was determined by
competition with a 1,000-fold excess of nonlabeled -BuTx and was
subtracted from the total binding. Each data point is the mean of
triplicate determinations. A Scatchard plot of the data is shown in the
inset. Panel B, linear relationship of 211
protein concentration and toxin binding at saturation concentration
(500 nM) of -125I-BuTx. The binding reaction
was carried out in a total volume of 0.25 ml for each data point.
Nonspecific binding was determined by competition with a 500-fold
excess of nonlabeled -BuTx and was subtracted from the total
binding.
|
|
The kinetics of association between toxin and 211 was shown to be of
second order with an association rate constant
kon = 1.06 × 106
M 1 s 1 (Fig.
6). To determine the kinetics of
dissociation, the binding reaction was allowed to reach equilibrium (90 min), and an excess of nonlabeled 20 µM -BuTx was then
added to initiate dissociation. The dissociation kinetics was of first
order, yielding the rate constant koff = 0.21 × 10 3 s 1. The dissociation
constant KD calculated from the association and
dissociation rates
(koff/kon) is 0.2 nM. This value is close to those obtained previously with
the native AChRs (59-61) but is considerably lower than those with
bacteria-expressed extracellular domains (KD = 130 nM) (37) or with synthetic peptides corresponding to
subunit sequence (KD = 10 µM)
(18-20). Thus, we conclude that the yeast-expressed 211 protein
appears to assume a conformation very close to that in the native AChR
subunit.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 6.
Kinetics of association and dissociation of
125I- -BuTx and
211 protein. Top, 10 nM
purified 211 protein was incubated with 25 nM
-125I-BuTx at room temperature. Aliquots were removed at
the times indicated and assayed for receptor-toxin complex using Ni-NTA
minicolumns. Panel B, to study the kinetics of dissociation
(koff), toxin binding was allowed to reach
equilibrium (90 min). Excess cold 20 µM toxins were then
added to initiate dissociation, and the amount of bound
-125I-BuTx was determined at the indicated times by
filtering the sample through the Ni-NTA columns.
|
|
The affinity of 211 to small cholinergic ligands was determined by
equilibrium competition assays using 6 nM
-125I-BuTx as radioligand and acetylcholine,
d-tubocurarine, and nicotine as competing reagents. Based on
the IC50 concentrations of competing ligands,
KI values were calculated using the Cheng and
Prusoff equation (50) as 1.3 × 10 4 M,
3.3 × 10 4 M, and 4.2 × 10 5 M, respectively, for acetylcholine,
d-tubocurarine, and nicotine (Fig.
7). These results are consistent with
previous studies demonstrating that the subunit alone does not bind
cholinergic ligands well, and formation of high affinity ACh binding
sites involves protein domains from adjacent and subunits
in the receptor pentamer (2, 11, 12).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 7.
Competition binding assays with small
cholinergic ligands. The concentrations of 211 protein and
-125I-BuTx were kept constant at 1 and 5 nM,
respectively. Toxin binding activity in the absence of small ligands
was normalized to 100%, and the amount of bound ligands was calculated
from the reduction in -125I-BuTx binding.
|
|
Biophysical Properties of 211 Protein--
Unlike receptor
fragments made with bacterial expression system (38), the
yeast-generated 211 protein remained soluble at concentrations up to
1 mM (~30 mg/ml) in 50 mM phosphate buffer (pH 8.0). Ultracentrifugation on a sucrose gradient displayed a single
peak of -125I-BuTx binding activity at ~4.5 S,
suggesting that the receptor domain is a monomer (Fig.
8A). Secondary structure
analysis of CD spectra indicated that the protein contained
considerable -pleated sheets with only a small amount of -helical
structure (14% -helix, 46% -sheet, 21% -turn, and 19%
random coils based on the CDPro program, Fig. 8B). This
composition of 211 is very close to that of a
glycosylphosphatidylinositol-linked mouse 210 protein
expressed on surface of CHO cells (33).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 8.
Biophysical characterization of the
211 protein. Panel A, analysis by
sucrose gradient sedimentation. Purified 211 protein was
concentrated to 1 mM, and an aliquot of the sample was
separated on 3-30% sucrose gradients. The fractions were assayed for
-125I-BuTx binding activity as described under
"Experimental Procedures." Panel B, analysis of 100 µM 211 in 20 mM Tris (pH 7.4) at 22 °C
by CD spectrometry. The CD spectra show that the protein fragment is
rich in -sheet structure.
|
|
NMR Analysis of 211 Protein in Solution--
The high
solubility of 211 protein facilitates protein structural studies
using NMR spectroscopy. Moreover, the optimal growth of
Pichia in minimal medium has allowed us to label 211
using [15N]ammonium sulfate. The labeled receptor protein
was concentrated to 10 mg/ml (0.32 mM) in the absence of
detergent and used for multidimensional NMR analysis. By measuring the
1H spectra and 1H-15N HSQC spectra
(Fig. 9), we have optimized the sample
conditions (salt concentration, pH, and temperature) to narrow the
resonance line widths. At lower pH values (pH 4-7) more suitable for
protein NMR, 211 precipitated at 35 °C, and T2 measurements
indicated protein aggregation. At pH 7.4, 211 precipitation was
minimal, but amide protons were subject to a faster exchange rate,
which could result in the disappearance of amide protons in flexible regions of the protein. The incorporation of water flip-back pulses and
WATERGATE water suppression into the pulse sequences, as well as
measurement at lower temperatures (25 °C) partially alleviated the
difficulties caused by the faster exchange rate. Of 215 expected cross-peaks (227 amino acids of which 12 are prolines) 195 cross-peaks were observed, a remarkable achievement considering the low
concentration of 211 (0.32 mM), the short measurement
time (75 min), and the expected partial overlap in a two-dimensional
spectrum of a protein of this size. Both the HSQC and the NOESY spectra
showed that the proton resonances are well dispersed, highly indicative
of a folded protein. Our initial NMR studies thus suggest that the yeast-expressed receptor domain is amenable to further high
resolution multidimensional NMR analysis.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 9.
NMR study of the 211
protein in solution. Panel A, a two-dimensional
sensitivity-enhanced TROSY-15N-1H HSQC.
Panel B, a representative plane of a TROSY three-dimensional
15N-separated NOESY spectrum of 211 protein measured at
25 °C. The spectra were measured on a Bruker 800 MHz spectrometer at
a protein concentration of 10 mg/ml (0.32 mM) in 50 mM sodium phosphate (pH 7.4) and 50 mM sodium
chloride.
|
|
 |
DISCUSSION |
In the present study, we have reported expression of the entire
amino-terminal extracellular domain of mouse muscle AChR subunit in
a native-like form using P. pastoris. Several lines of
evidence suggest that the 211 protein we produced is properly folded. First, the receptor fragment was expressed as a secreted protein in Pichia, and it remained soluble at high
concentrations. Second, the protein bound the competitive antagonist
-BuTx with affinities approaching those reported for the native AChR
pentamers in muscle and Torpedo electric organ (59-61). In
addition, CD spectra showed that the receptor domain displays a
composition of secondary structure similar to a membrane-anchored
210 protein expressed in Chinese hamster ovary cells (33).
Furthermore, the proton resonances of 211 are well dispersed in NMR
spectra, suggesting that the recombinant yeast protein assumes a folded
conformation suitable for structural determination at high resolution.
Extracellular domains of the AChR have been expressed before as soluble
proteins using transfected mammalian cell lines and baculovirus-infected insect cells (33, 34, 39). The receptor fragments
were able to fold properly in these systems, but the quantities of
protein produced were insufficient for crystallization or NMR
determination. The full-length subunits of Torpedo AChR have
also been expressed using S. cerevisiae. The yeast system, however, failed to yield functional proteins presumably because of
insufficient cleavage of receptor signal sequences. Moreover, polypeptides of AChR subunits assumed wrong orientations in the endoplasmic reticular membrane of S. cerevisiae (62-64).
Recently, the extracellular fragments of Torpedo AChR subunit have been produced in inclusion bodies of bacteria in
quantities sufficient for structural studies (36-38). This approach,
however, has proven to be problematic because of the denaturing
conditions required to solubilize the protein as well as the difficulty
in refolding the receptor domain. Furthermore, bacteria-generated
receptor fragments are not suitable for structural studies because they aggregate at high concentrations presumably resulting from the absence
of post-translational modifications (38).
In the present study, we show that the length of extracellular domain
is critical to the soluble expression of the receptor protein in
Pichia. Protein fragments with part of ( 216) or the entire first transmembrane domain ( M1) were not secreted by
Pichia and were probably retained in yeast endoplasmic
reticulum as integral membrane proteins. In our previous study, they
were shown to be resistant to extraction by alkaline buffers from
membranes of transfected COS cells (39). Other laboratories have
employed 210, the entire amino-terminal extracellular domain of the
subunit, as well as fragments 209 and 208 for protein
expression in Chinese hamster ovary cells, baculovirus-infected insect
cells, and bacteria (33, 34, 36, 37). In the present study, however, we
found that these shorter fragments were secreted in low levels by
Pichia. Maximal protein expression was obtained with 211, which contains a proline residue in the first transmembrane domain of
the subunit sequence. Because the synthetic peptide derived from
amino acid sequence 173-204 of Torpedo subunit can bind -BuTx (19), it seems unlikely that residue 211 participates directly
in interacting with the toxin molecule. Instead, the proline residue in
the first transmembrane domain may be critical for peptide folding to
acquire a proper tertiary structure with an accessible high affinity
toxin binding site. Alternatively, it may help to stabilize the
receptor protein in yeast (39).
In agreement with the x-ray structure of the snail AChBP (28), the CD
spectra of the yeast-expressed 211 indicate that the protein
contains considerable -pleated sheets with only a small amount of
-helical structure. The 14% of -helical conformation measured by
CD represents ~30 amino acids in 211 protein. In contrast, only 12 residues in the amino terminus of the snail AChBP were found to be in
the -helix (28). This discrepancy is not surprising in view of the
low sequence identity between the AChBP and muscle AChR (29). In fact,
the composition of 211 revealed by CD is consistent with early
amphipathic analysis of Torpedo AChR sequences (65). It is
also very close to that of a glycosylphosphatidylinositol-linked
mouse 210 protein expressed on the surface of Chinese hamster ovary
cells (33).
The yeast P. pastoris reported here offers several major
advantages over other expression systems adopted previously for AChR expression. First, it is faster and less expensive to use than mammalian or insect cells and gives higher expression levels. Although
the concentration of 211 in the culture medium is relatively lower
compared with other secretory proteins that have been produced with
Pichia before (57, 58), the addition of a FLAG tag to the
amino terminus of 211 could increase the yield considerably. This
effect is likely the result an enhanced solubility of the receptor
protein because the tag sequence is rich in charged residues. Alternatively, the presence of FLAG tag at the amino terminus may help
to facilitate signal peptide cleavage.
Although it is as easy to manipulate as Escherichia coli,
the expression system we report here is superior to bacteria with regard to the efficiency of protein processing and folding. In Pichia, the yeast signal peptide is cleaved completely from
211 sequence, a key step that allows the receptor protein to enter the secretory pathway where it is folded properly to assume ligand binding activity (44, 64). In addition, the 211 protein was modified
by N-linked glycosylation in Pichia, and the
oligosaccharide chain was cleavable by Endo H. Many secretory proteins
have been found to be hyperglycosylated in S. cerevisiae
(50-150 mannose residues/side chain). In P. pastoris,
however, the length of sugars added post-translationally to proteins
usually averages 8-14 mannose residues, thus resembling the
glycoprotein structure of higher eukaryotes (66-68). Glycosylation of
211 appeared to be homogeneous on SDS-PAGE, and it increased
the size of the protein by ~3 kDa. The extracellular domain of AChR
subunit is known to possess a putative consensus sequence for
glycosylation on residue Asn141. Previous studies have
detected N-linked oligosaccharides of similar size and
composition on subunit purified from skeletal muscle or expressed
in heterologous systems (10, 31-33, 39, 69, 70). Accumulating evidence
suggests that the N-linked glycosylation is required for
efficient protein folding and secretion (69-71). A further advantage
of the post-translational modification in yeast is the enhanced
solubility of the recombinant protein. Biophysical studies using
sucrose gradient ultracentrifugation, CD, and NMR spectroscopy all
suggest that the 211 protein remains in a nonaggregated state even
at high concentrations. Although glycosylation may sometimes render it
difficult to crystallize proteins for x-ray diffraction, it generally
does not interfere with protein structural determination by NMR.
Indeed, the dispersed spectra of 211 in our HSQC and NOESY
experiments support this notion. Finally, yeast cells are capable of
secreting the receptor domain when they are grown in minimal medium
supplemented with sorbitol, thereby enabling labeling of protein
backbone by 15N and C13 for multidimensional
NMR studies.
In summary, we have described a yeast expression system for production
of a soluble extracellular domain of AChR subunit. Pharmacological
and biophysical studies suggest that the 211 protein appears to be
suitable for structural determination by multidimensional NMR and for
crystallization. Because the AChR is highly homologous to other members
of the ligand-gated ion channel family including -aminobutyric acid,
glycine, and the serotonin receptors (1, 2), the approach we introduce
here may open a new avenue for large scale production of soluble
domains of these proteins. Because the receptors are known to be
targets of drugs for pain management, treatment of mental illness, and other pathological events such as seizure and stroke, their high resolution structure information is essential to the rational design of
more specific and effective therapeutic agents.
 |
ACKNOWLEDGEMENTS |
We are grateful to Dr. Zach Hall for help and
encouragement in the early stage of this study. We thank Dr. Michael
Cascio (University of Pittsburgh) for advice in CD spectrophotometry.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant NS38301, the Muscular Dystrophy Association, a Competitive Medical Research Fund award from the University of Pittsburgh (to Z.-Z. W.), and by United States-Israel Binational Science Foundation Grant 98-328 (to J. A.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Joseph and Ruth Owades Professor in chemistry.
To whom correspondence should be addressed: Dept. of
Neurobiology, University of Pittsburgh School of Medicine, 3500 Terrace St., E1440 BST, Pittsburgh, PA 15261. Tel.: 412-648-9421; Fax: 412-383-8663; E-mail: zzwang@pitt.edu.
Published, JBC Papers in Press, January 25, 2002, DOI 10.1074/jbc.M108845200
 |
ABBREVIATIONS |
The abbreviations used are:
AChR(s), acetylcholine receptor(s);
-BuTx, -bungarotoxin;
AChBP, acetylcholine-binding protein;
211, recombinant fragment of the
amino-terminal extracellular region (amino acid 1-211) of the subunit of the AChR;
Endo H, endoglycosidase H;
HSQC, heteronuclear
single quantum coherence;
IEF, isoelectric focusing;
mAb, monoclonal antibody;
Ni-NTA, nickel-nitrilotriacetic acid;
NOESY, nuclear Overhauser effect spectroscopy;
TROSY, transverse
relaxation-optimized spectroscopy.
 |
REFERENCES |
| 1.
|
Betz, H.
(1990)
Neuron
5,
383-392[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Karlin, A.,
and Akabas, M. H.
(1995)
Neuron
15,
1231-1244[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Claudio, T.
(1989)
in
Frontiers in Molecular Biology: Molecular Neurobiology
(Glover, D. M.
, and Hames, B. D., eds)
, pp. 63-142, IRL Press, Oxford
|
| 4.
|
Galzi, J. L.,
Revah, F.,
Bessis, A.,
and Changeux, J. P.
(1991)
Annu. Rev. Pharmacol. Toxicol.
31,
37-72[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Karlin, A.,
Holtzman, E.,
Yodh, N.,
Lobel, P.,
Wall, J.,
and Hainfeld, J.
(1983)
J. Biol. Chem.
258,
6678-6681[Abstract/Free Full Text]
|
| 6.
|
Karlin, A.
(1989)
Harvey Lect.
85,
71-107[Medline]
[Order article via Infotrieve]
|
| 7.
|
Machold, J.,
Weise, C.,
Utkin, Y.,
Tsetlin, V.,
and Hucho, F.
(1995)
Eur. J. Biochem.
234,
427-430[Medline]
[Order article via Infotrieve]
|
| 8.
|
Noda, M.,
Takahashi, H.,
Tanabe, T.,
Toyosato, M.,
Kikyotani, S.,
Furutani, Y.,
Hirose, T.,
Takashima, H.,
Inayama, S.,
Miyata, T.,
and Numa, S.
(1983)
Nature
302,
528-532[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Karlin, A.
(1993)
Curr. Opin. Neurobiol.
3,
299-309[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Chavez, R. A.,
and Hall, Z. W.
(1991)
J. Biol. Chem.
266,
15532-15538[Abstract/Free Full Text]
|
| 11.
|
Sine, S. M.,
and Claudio, T.
(1991)
J. Biol. Chem.
266,
19369-19377[Abstract/Free Full Text]
|
| 12.
|
Blount, P.,
and Merlie, J. P.
(1989)
Neuron
3,
349-357[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Haggerty, J. G.,
and Froehner, S. C.
(1981)
J. Biol. Chem.
256,
8294-8297[Abstract/Free Full Text]
|
| 14.
|
Oswald, R. E.,
and Changeux, J. P.
(1982)
FEBS Lett.
139,
225-229[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Lentz, T. L.,
and Wilson, P. T.
(1988)
Int. Rev. Neurobiol.
29,
117-160[Medline]
[Order article via Infotrieve]
|
| 16.
|
Chatrenet, B.,
Tremeau, O.,
Bontems, F.,
Goeldner, M. P.,
Hirth, C. G.,
and Menez, A.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
3378-3382[Abstract/Free Full Text]
|
| 17.
|
Tzartos, S. J.,
Barkas, T.,
Cung, M. T.,
Mamalaki, A.,
Marraud, M.,
Orlewski, P.,
Papanastasiou, D.,
Sakarellos, C.,
Sakarellos-Daitsiotis, M.,
Tsantili, P.,
and Tsikaris, V.
(1998)
Immunol. Rev.
163,
89-120[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Neumann, D.,
Barchan, D.,
Fridkin, M.,
and Fuchs, S.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
9250-9253[Abstract/Free Full Text]
|
| 19.
|
Wilson, P. T.,
Hawrot, E.,
and Lentz, T. L.
(1988)
Mol. Pharmacol.
34,
643-650[Abstract]
|
| 20.
|
Ohana, B.,
and Gershoni, J. M.
(1990)
Biochemistry
29,
6409-6415[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Tzartos, S. J.,
Rand, D. E.,
Einarson, B. L.,
and Lindstrom, J. M.
(1981)
J. Biol. Chem.
256,
8635-8645[Abstract/Free Full Text]
|
| 22.
|
Tzartos, S. J.,
Kokla, A.,
Walgrave, S. L.,
and Conti-Tronconi, B. M.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
2899-2903[Abstract/Free Full Text]
|
| 23.
|
Samson, A. O.,
Chill, J. H.,
Rodriguez, E.,
Scherf, T.,
and Anglister, J.
(2001)
Biochemistry
40,
5464-5473[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Zeng, H.,
Moise, L.,
Grant, M. A.,
and Hawrot, E.
(2001)
J. Biol. Chem.
276,
22930-22940[Abstract/Free Full Text]
|
| 25.
|
Sine, S. M.
(1997)
J. Biol. Chem.
272,
23521-23527[Abstract/Free Full Text]
|
| 26.
|
Spura, A.,
Russin, T. S.,
Freedman, N. D.,
Grant, M.,
McLaughlin, J. T.,
and Hawrot, E.
(1999)
Biochemistry
38,
4912-4921[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Miyazawa, A.,
Fujiyoshi, Y.,
Stowell, M.,
and Unwin, N.
(1999)
J. Mol. Biol.
288,
765-786[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Brejc, K.,
van Dijk, W. J.,
Klaassen, R. V.,
Schuurmans, M.,
van Der Oost, J.,
Smit, A. B.,
and Sixma, T. K.
(2001)
Nature
411,
269-276[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Smit, A. B.,
Syed, N. I.,
Schaap, D.,
van Minnen, J.,
Klumperman, J.,
Kits, K. S.,
Lodder, H.,
van der Schors, R. C.,
van Elk, R.,
Sorgedrager, B.,
Brejc, K.,
Sixma, T. K.,
and Geraerts, W. P. M.
(2001)
Nature
411,
261-268[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Mayne, K. M.,
Yoshii, K., Yu, L.,
Lester, H. A.,
and Davidson, N.
(1987)
Brain Res.
388,
191-197[Medline]
[Order article via Infotrieve]
|
| 31.
|
Blount, P.,
and Merlie, J. P.
(1988)
J. Biol. Chem.
263,
1072-1080[Abstract/Free Full Text]
|
| 32.
|
Forsayeth, J. R.,
Franco, A., Jr.,
Rossi, A. B.,
Lansman, J. B.,
and Hall, Z. W.
(1990)
J. Neurosci.
10,
2771-2779[Abstract]
|
| 33.
|
West, A. P., Jr.,
Bjorkman, P. J.,
Dougherty, D. A.,
and Lester, H. A.
(1997)
J. Biol. Chem.
272,
25468-25473[Abstract/Free Full Text]
|
| 34.
|
Tierney, M. L.,
and Unwin, N.
(2000)
J. Mol. Biol.
303,
185-196[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Gershoni, J. M.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
4318-4321[Abstract/Free Full Text]
|
| 36.
|
Schrattenholz, A.,
Pfeiffer, S.,
Pejovic, V.,
Rudolph, R.,
Godovac-Zimmermann, J.,
and Maelicke, A.
(1998)
J. Biol. Chem.
273,
32393-32399[Abstract/Free Full Text]
|
| 37.
|
Alexeev, T.,
Krivoshein, A.,
Shevalier, A.,
Kudelina, I.,
Telyakova, O.,
Vincent, A.,
Utkin, Y.,
Hucho, F.,
and Tsetlin, V.
(1999)
Eur. J. Biochem.
259,
310-319[Medline]
[Order article via Infotrieve]
|
| 38.
|
Grant, M. A.,
Gentile, L. N.,
Shi, Q. L.,
Pellegrini, M.,
and Hawrot, E.
(1999)
Biochemistry
38,
10730-10742[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Wang, Z. Z.,
Hardy, S. F.,
and Hall, Z. W.
(1996)
J. Biol. Chem.
271,
27575-27584[Abstract/Free Full Text]
|
| 40.
|
Wang, Z. Z.,
Hardy, S. F.,
and Hall, Z. W.
(1996)
J. Cell Biol.
135,
809-817[Abstract/Free Full Text]
|
| 41.
|
Isenberg, K. E.,
Mudd, J.,
Shah, V.,
and Merlie, J. P.
(1986)
Nucleic Acids Res.
14,
5111[Free Full Text]
|
| 42.
|
Gullick, W. J.,
and Lindstrom, J. M.
(1983)
Biochemistry
22,
3312-3320[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Ratnam, M.,
Sargent, P. B.,
Sarin, V.,
Fox, J. L.,
Nguyen, D. L.,
Rivier, J.,
Criado, M.,
and Lindstrom, J.
(1986)
Biochemistry
25,
2621-2632[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Brake, A. J.,
Merryweather, J. P.,
Coit, D. G.,
Heberlein, U. A.,
Masiarz, F. R.,
Mullenbach, G. T.,
Urdea, M. S.,
Valenzuela, P.,
and Barr, P. J.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
81,
4642-4646[Abstract/Free Full Text]
|
| 45.
|
Cregg, J. M.,
Barringer, K. J.,
Hessler, A. Y.,
and Madden, K. R.
(1985)
Mol. Cell. Biol.
5,
3376-3385[Abstract/Free Full Text]
|
| 46.
|
Ellis, S. B.,
Brust, P. F.,
Koutz, P. J.,
Waters, A. F.,
Harpold, M. M.,
and Gingeras, T. R.
(1985)
Mol. Cell. Biol.
5,
1111-1121[Abstract/Free Full Text]
|
| 47.
|
Cregg, J. M.,
Madden, K. R.,
Barringer, K. J.,
Thill, G. P.,
and Stillman, C. A.
(1989)
Mol. Cell. Biol.
9,
1316-1323[Abstract/Free Full Text]
|
| 48.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Weiland, G. A.,
and Molinoff, P. B.
(1981)
Life Sci.
29,
313-330[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Cheng, Y.,
and Prusoff, W. H.
(1973)
Biochem. Pharmacol.
22,
3099-3108[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Pervushin, K.,
Wider, G.,
and Wuthrich, K.
(1998)
J. Biomol. NMR
12,
345-348[CrossRef]
|
| 52.
|
Zhu, G.,
Kong, X. M.,
and Sze, K. H.
(1999)
J. Biomol. NMR
13,
77-81
|
| 53.
|
Grzesiek, S.,
and Bax, A.
(1993)
J. Am. Chem. Soc.
115,
12593-12594[CrossRef]
|
| 54.
|
Grzesiek, S.,
Bax, A., Hu, J. S.,
Kaufman, J.,
Palmer, I.,
Stahl, S. J.,
Tjandra, N.,
and Wingfield, P. T.
(1997)
Protein Sci.
6,
1248-1263[Medline]
[Order article via Infotrieve]
|
| 55.
|
Piotto, M.,
Saudek, V.,
and Sklenar, V.
(1992)
J. Biomol. NMR
2,
661-665[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Delaglio, F.,
Grzesiek, S.,
Vuister, G. W.,
Zhu, G.,
Pfeifer, J.,
and Bax, A.
(1995)
J. Biomol. NMR
6,
277-293[Medline]
[Order article via Infotrieve]
|
| 57.
|
Clare, J. J.,
Romanos, M. A.,
Rayment, F. B.,
Rowedder, J. E.,
Smith, M. A.,
Payne, M. M.,
Sreekrishna, K.,
and Henwood, C. A.
(1991)
Gene (Amst.)
105,
205-212[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Chen, Y.,
Krol, J.,
Cino, J.,
Freedman, D.,
White, C.,
and Komives, E.
(1996)
J. Chem. Tech. Biotechnol.
67,
143-148[CrossRef]
|
| 59.
|
Blanchard, S. G.,
Quast, U.,
Reed, K.,
Lee, T.,
Schimerlik, M. I.,
Vandlen, R.,
Claudio, T.,
Strader, C. D.,
Moore, H. P.,
and Raftery, M. A.
(1979)
Biochemistry
18,
1875-1883[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Maelicke, A.,
Fulpius, B. W.,
Klett, R. P.,
and Reich, E.
(1977)
J. Biol. Chem.
252,
4811-4830[Free Full Text]
|
| 61.
|
Tzartos, S. J.,
and Changeux, J. P.
(1984)
J. Biol. Chem.
259,
11512-11519[Abstract/Free Full Text]
|
| 62.
|
Fujita, N.,
Nelson, N.,
Fox, T. D.,
Claudio, T.,
Lindstrom, J.,
Riezman, H.,
and Hess, G. P.
(1986)
Science
231,
1284-1287[Abstract/Free Full Text]
|
| 63.
|
Jansen, K. U.,
Conroy, W. G.,
Claudio, T.,
Fox, T. D.,
Fujita, N.,
Hamill, O.,
Lindstrom, J. M.,
Luther, M.,
Nelson, N.,
Ryan, K. A.,
Sweet, M. T.,
and Hess, G. P.
(1989)
J. Biol. Chem.
264,
15022-15027[Abstract/Free Full Text]
|
| 64.
|
Yellen, G.,
and Migeon, J. C.
(1990)
Gene (Amst.)
86,
145-152[CrossRef][Medline]
[Order article via Infotrieve]
|
| 65.
|
Finer-Moore, J.,
and Stroud, R.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
81,
155-159[Abstract/Free Full Text]
|
| 66.
|
Grinna, L. S.,
and Tschopp, J. F.
(1989)
Yeast
5,
107-115[CrossRef][Medline]
[Order article via Infotrieve]
|
| 67.
|
Tschopp, J. F.,
Sverlow, G.,
Kosson, R.,
Craig, W.,
and Grinna, L. S.
(1987)
Bio/Technology
5,
1305-1308[CrossRef]
|
| 68.
|
Cregg, J. M.,
Vedvick, T. S.,
and Raschke, W. C.
(1993)
Bio/Technology
11,
905-910
|
| 69.
|
Prives, J.,
and Bar-Sagi, D.
(1983)
J. Biol. Chem.
258,
1775-1780[Abstract/Free Full Text]
|
| 70.
|
Blount, P.,
and Merlie, J. P.
(1990)
J. Cell Biol.
111,
2613-2622[Abstract/Free Full Text]
|
| 71.
|
Marquardt, T.,
and Helenius, A.
(1992)
J. Cell Biol.
117,
505-513[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. M. Person, K. L. Bills, H. Liu, S. K. Botting, J. Lindstrom, and G. B. Wells
Extracellular Domain Nicotinic Acetylcholine Receptors Formed by {alpha}4 and {beta}2 Subunits
J. Biol. Chem.,
December 2, 2005;
280(48):
39990 - 40002.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Breitinger, H.-G. Breitinger, F. Bauer, K. Fahmy, D. Glockenhammer, and C.-M. Becker
Conserved High Affinity Ligand Binding and Membrane Association in the Native and Refolded Extracellular Domain of the Human Glycine Receptor {alpha}1-Subunit
J. Biol. Chem.,
January 16, 2004;
279(3):
1627 - 1636.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-W. Chi, K.-H. Park, J.-E. Suk, B. M. Olivera, J. M. McIntosh, and K.-H. Han
Solution Conformation of {alpha}A-conotoxin EIVA, a Potent Neuromuscular Nicotinic Acetylcholine Receptor Antagonist from Conus ermineus
J. Biol. Chem.,
October 24, 2003;
278(43):
42208 - 42213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Psaridi-Linardaki, A. Mamalaki, M. Remoundos, and S. J. Tzartos
Expression of Soluble Ligand- and Antibody-binding Extracellular Domain of Human Muscle Acetylcholine Receptor alpha Subunit in Yeast Pichia pastoris. ROLE OF GLYCOSYLATION IN alpha -BUNGAROTOXIN BINDING
J. Biol. Chem.,
July 19, 2002;
277(30):
26980 - 26986.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|